Hamel Lawrence G 4
4 · ACELRX PHARMACEUTICALS INC · Filed Sep 5, 2018
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Award
Common Stock
2018-08-31$1.49/sh+6,876$10,245→ 24,371 total
Holdings
- 41,964(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]These shares were acquired under the Company's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]Non-reportable acquisition of 1,116 shares of common stock through the Company's Employee Stock Purchase Plan.